TEMA HEART & HEALTH ETF (HRTS) Report

The TEMA HEART & HEALTH ETF (ticker: HRTS) is an exchange-traded fund listed on the NASDAQ. This ETF focuses on companies within the health and heart sectors.

What this ETF is trying to do

HRTS provides investors with exposure to a variety of companies in the healthcare space. Based on its top holdings, the fund invests in large pharmaceutical and medical technology companies. The goal is to track the performance of these specific health-related businesses.

What the numbers show

The current price of HRTS is $35.67. Looking at historical performance, the numbers show growth over the last year:

• Year-to-Date (YTD) Price Return: The share price has increased by approximately 1.09% since the start of the year.

• One-Year Price Return: The share price has grown by approximately 10.11% over the last twelve months.

• One-Year Total Return: When including distributions, the total return for the last year was approximately 11.61%.

An estimated price from roughly one year ago was $32.40.

Income and distribution explanation

This ETF provides some cash income through distributions. The distribution yield is approximately 1.33%. It is important to remember that the distribution yield is a measure of cash paid out relative to the price; it is not the same as the total return.

The data shows that distributions for this fund are "irregular" or "less frequent." In the last 12 months, there was only one payout recorded.

NAV erosion explanation

"NAV erosion" refers to a decline in the Net Asset Value (the actual value of the assets held by the fund). The supplied data is sufficient to evaluate price erosion, but it does not include enough historical NAV-per-share data to confirm or rule out NAV erosion.

However, regarding price movement, the fund has an erosion-risk score of 100, which is labeled as "No price erosion detected." The erosion severity is rated as "good," and there is no severe erosion-risk flag present.

Top Holdings

The following are the top holdings in the portfolio (note that this is a partial list):

• ELI LILLY AND CO (11.45%)

• THERMO FISHER SCIENTIFIC INC (5.77%)

• UNITEDHEALTH GROUP INC (4.64%)

• MERCK & CO INC (4.37%)

• NOVO NORDISK AS CLASS B (4.16%)

• REVOLUTION MEDICINES INC (3.78%)

• ROCHE HOLDING AG ADR (3.74%)

• JOHNSON & JOHNSON (3.67%)

• CYTOKINETICS INC (3.37%)

• GILEAD SCIENCES INC (3.28%)

Holdings can change over time. This data was updated on October 7, 2026.

Pros

• The fund has shown positive price returns over the last year.

• The erosion-risk score suggests no significant price erosion has been detected.

Cons

• Distributions are irregular and infrequent, which may not suit investors looking for steady monthly income.

Beginner takeaway

HRTS is a healthcare-focused ETF that has seen its share price increase over the past year. While it pays a distribution, the payments are not frequent. Investors should distinguish between the share-price increase (price return) and the total amount earned including distributions (total return).